Quantum Surgical Acquires NeuWave Medical

February 27, 2026—Quantum Surgical, a medical device company specializing in minimally invasive robotic-assisted cancer treatment, announced the acquisition of NeuWave Medical, Inc.

The press release noted that Quantum Surgical developed the Epione robotic platform for treating early-stage tumors. Epione assists physicians in performing percutaneous tumor ablations. NeuWave Medical markets a microwave ablation technology for percutaneous ablations.

The Epione device has received CE Mark approval for abdominal, chest, and musculoskeletal structures indications. In the United States, it is FDA cleared for the abdominal ablation indication. NeuWave’s microwave ablation technology is available in the United States, where it is used in leading cancer centers, advised the press release.

According to Quantum Surgical, the acquisition supports its strategy to democratize robotic-assisted tumor ablation treatments to reduce cancer mortality. The two companies will operate as subsidiaries of Precision IO Group Inc., a newly created parent company led by medtech veteran Kurt Azarbarzin, who was recently appointed CEO.

Precision IO Group is working on a new remote interventions project that aims to expand access to robotic-assisted percutaneous procedures by leveraging world-renowned experts for remote trajectory planning and results assessment, using Epione tools.

Both companies will continue to operate independently to ensure a smooth and uninterrupted experience for their users while the companies’ activities complement each other and robust, cross-organizational enhancements are being developed, noted the press release.